- A Yale study finds that Tocilizumab, when given to the most severely ill COVID-19 patients— specifically, those experiencing a dangerous immune response known as a “cytokine storm”—it appeared to improve survival rates up to 87%, especially among patients requiring mechanical ventilation. https://journal.chestnet.org/article/s0012-3692(20)31670-6/fulltext 118 comments science
Linked pages
Related searches:
Search whole site: site:journal.chestnet.org
Search title: Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 - CHEST
See how to search.